article30 June 2016 | By Diarmuid Ryan (Squire Patton Boggs), Martin Rees (Squire Patton Boggs)
Many features of the pharmaceutical sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid, play a crucial role in incentivising new product research and development. On the other hand, the European Commission and the various national…